Biotechnologist I

OXB; Oxford; On-site; GBP 30,000 - 50,000; Full time

Job summary

A leading viral vector CDMO in Oxford is seeking Biotechnologists to join the Manufacturing team. The role involves manufacturing viral vector batches in a GMP cleanroom, ensuring high standards of quality and safety. Ideal candidates should have a degree or equivalent experience, with a focus on detail and safety. This position offers a collaborative culture and opportunities for personal and professional development.

Benefits

Competitive total reward packages

Wellbeing programmes

Career development opportunities

Supportive culture

State-of-the-art labs

Qualifications

• Experience in a GMP manufacturing environment is advantageous.
• Prior experience in an aseptic environment is advantageous.
• Good writing skills and computer literacy.
• Flexibility to work shifts including early mornings, late nights, and weekends.

Responsibilities

• Manufacture commercial and clinical grade viral vector batches.
• Perform upstream and downstream processing of viral vector products.
• Maintain GMP facility and ensure batch success with aseptic techniques.
• Gather and monitor batch manufacturing records.

Skills

Attention to detail

Problem-solving

Interpersonal communication

Teamwork

Self-motivated

Education

Degree level qualification or equivalent experience

Job description

Join Us in Changing Lives

At OXB, our people are at the heart of everything we do. We’re on a mission to enable life‑changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful.

We’re currently recruiting for Biotechnologists at different levels to join our Manufacturing team. In this role, you will be manufacturing commercial and clinical grade viral vector batches within a GMP cleanroom facility, playing a key part in advancing our mission and making a real difference.

Your responsibilities in this role would be:

• Upstream adherent and/or suspension mammalian cell culture, transfection and harvest of viral vector products.
• Downstream processing including clarification, chromatography, ultra/diafiltration and fill/finish activities.
• Ensuring batch success by working using good aseptic techniques.
• Preparing, cleaning and maintaining the GMP facility including performing viable and non‑viable environmental monitoring.
• Preparating growth media and stock solutions using portable mixing tanks.
• Completing Batch Manufacturing Records in a timely fashion throughout the manufacturing process.
• Taking part in continuous improvement initiatives & development of production processes.
• Investigating quality incidents, deviations and improving procedures.
• Working to high standards of health & safety.

We are looking for:

• Working within a GMP manufacturing environment is advantageous but not essential.
• Degree level qualification or equivalent experience.
• Prior experience of working within an aseptic environment is advantageous but not essential.
• Self‑motivated with a strong focus on safety, quality, details, and results.
• Good problem‑solving, interpersonal communication and team skills.
• Excellent writing skills and computer literacy.
• Flexibility to work shifts including early mornings, late nights and weekends when required.

About Us:

OXB is a quality and innovation‑led viral vector CDMO with a mission to enable its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. OXB’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods, and depth of regulatory expertise.

Why Join Us?

• 💸 Competitive total reward packages
• 🧘 Wellbeing programmes that support your mental and physical health
• 🚀 Career development opportunities to help you grow and thrive
• 🤝 Supportive, inclusive, and collaborative culture
• 🧪 State‑of‑the‑art labs and manufacturing facilities
• 🌍 A company that lives its values: Responsible, Responsive, Resilient, Respect

We want you to feel inspired every day. At OXB, we’re future‑focused and growing fast. We succeed together—through passion, commitment, and teamwork.

Ready to Make a Difference?

Collaborate. Contribute. Change lives.

Oxford Biomedica is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in‑vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex‑vivo gene therapy or gene‑modified cell therapy).

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.